Business Standard

Wednesday, December 25, 2024 | 09:08 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Lupin's Goa plant gets 7 observations from USFDA, firm unperturbed

Says confident of resolving matter, does not share nature of observations

Lupin
Premium

Lupin

Sohini Das Mumbai
Mumbai-based drugmaker said on Sunday that its Goa facility has received seven observations from the US drug regulator. At present, five sites of Lupin either have warning letters of Official Action Indicated (OAI) status from the US Food and Drug Administration.

In a stock exchange notification, Lupin said: “We wish to inform you that the US FDA has concluded an inspection at our Goa facility in India. The inspection was carried out from September 6, 2021 to September 18, 2021 and closed with seven observations.” Exact revenue contribution from the Goa facility is not known.

The company, however, is confident
Topics : Lupin USFDA

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in